Fig. 4: High-dimensional data analysis distinguishes rCD5L therapeutic groups in high-grade CLP, and compares with responses of WT vs. CD5L− mice in mid-grade CLP.
From: CD5L as a promising biological therapeutic for treating sepsis
a Two-dimensional t-distributed stochastic neighbor embedding (t-SNE) visualization of cytokines, CFUs and neutrophil recruitment for a perplexity of 8. Each ellipse describes a phenotypic subtype and are derived from 36 different measurements (seven for WT, five for IP-treated, and six for the remaining groups). Measurements were log2 transformed and normalized by the mean value of the “untreated” or the CD5L− subgroups for each setup [intravenous (IV); intraperitoneal (IP) or WT/CD5L−]. b Linear discriminant analysis (LDA) biplot showing the overall profile of treatment of CLP with rCD5L administered IV or IP, and mid-grade CLP in WT or CD5L− mice. Ellipses show 95% confidence intervals for each treatment and vectors represent the contribution of each variable to the overall variance.
